Literature DB >> 12714395

Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia.

K Ohno-Matsui1, T Yoshida, S Futagami, K Yasuzumi, N Shimada, A Kojima, T Tokoro, M Mochizuki.   

Abstract

AIMS: To determine the incidence and predisposing findings for choroidal neovascularisation (CNV) in a large series of highly myopic patients.
METHODS: The medical records of 218 consecutive patients (325 eyes) with myopic fundus changes in the macula were reviewed. The incidence of CNV during a follow up of at least 3 years of highly myopic patients and identification of predisposing findings for the development of myopic CNV were examined.
RESULTS: Among 325 highly myopic eyes examined, 33 eyes (10.2%) developed myopic CNV. The incidence was higher (34.8%) among the fellow eyes of patients with pre-existing CNV than among eyes of patients without pre-existing CNV (6.1%). CNV developed in 3.7% with diffuse chorioretinal atrophy, in 20.0% with patchy atrophy, and in 29.4% with lacquer cracks.
CONCLUSION: Approximately one in 10 highly myopic eyes developed myopic CNV in average 130.2 months. Patchy atrophy and lacquer cracks were shown to be important predisposing findings for CNV development.

Entities:  

Mesh:

Year:  2003        PMID: 12714395      PMCID: PMC1771643          DOI: 10.1136/bjo.87.5.570

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  14 in total

1.  The Fuchs' spot: an ophthalmoscopic and fluorescein angiographic study.

Authors:  J H Levy; H M Pollock; B J Curtin
Journal:  Ann Ophthalmol       Date:  1977-11

2.  Macular complications associated with posterior staphyloma.

Authors:  S M Steidl; R C Pruett
Journal:  Am J Ophthalmol       Date:  1997-02       Impact factor: 5.258

3.  Axial length measurements and fundus changes of the myopic eye.

Authors:  B J Curtin; D B Karlin
Journal:  Am J Ophthalmol       Date:  1971-01       Impact factor: 5.258

4.  Pathologic myopia and choroidal neovascularization.

Authors:  M L Hotchkiss; S L Fine
Journal:  Am J Ophthalmol       Date:  1981-02       Impact factor: 5.258

Review 5.  Myopic macular degeneration.

Authors:  M F Rabb; I Garoon; F P LaFranco
Journal:  Int Ophthalmol Clin       Date:  1981

6.  Posterior staphyloma development in pathologic myopia.

Authors:  B J Curtin
Journal:  Ann Ophthalmol       Date:  1982-07

7.  Visual prognosis of disciform degeneration in myopia.

Authors:  G R Hampton; D Kohen; A C Bird
Journal:  Ophthalmology       Date:  1983-08       Impact factor: 12.079

Review 8.  Physiologic vs pathologic myopia: genetics vs environment.

Authors:  B J Curtin
Journal:  Ophthalmology       Date:  1979-05       Impact factor: 12.079

9.  Common causes of blindness and visual handicap in the west of Scotland.

Authors:  I M Ghafour; D Allan; W S Foulds
Journal:  Br J Ophthalmol       Date:  1983-04       Impact factor: 4.638

10.  Prevalence of myopia in the United States.

Authors:  R D Sperduto; D Seigel; J Roberts; M Rowland
Journal:  Arch Ophthalmol       Date:  1983-03
View more
  60 in total

1.  Outcome of photodynamic therapy in choroidal neovascularization due to pathologic myopia and related factors.

Authors:  Tugrul Altan; Nur Acar; Ziya Kapran; Yaprak B Unver; Sezin Ozdogan
Journal:  Int Ophthalmol       Date:  2012-02-19       Impact factor: 2.031

2.  Contrast sensitivity after intravitreal antivascular endothelial growth factor therapy for myopic choroidal neovascularization.

Authors:  Sarah Moussa; Siamak Ansari-Shahrezaei; Eva Smretschnig; Stefan Hagen; Kerstin Steindl-Kuscher; Ilse Krebs; Susanne Binder
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-03-16       Impact factor: 3.117

Review 3.  Optical coherence tomography and pathological myopia: an update of the literature.

Authors:  Maria Vittoria Cicinelli; Luisa Pierro; Marco Gagliardi; Francesco Bandello
Journal:  Int Ophthalmol       Date:  2015-08-12       Impact factor: 2.031

4.  Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization.

Authors:  T Y Y Lai; F O J Luk; G K Y Lee; D S C Lam
Journal:  Eye (Lond)       Date:  2012-05-18       Impact factor: 3.775

Review 5.  Choroidal neovascularisation in pathological myopia: an update in management.

Authors:  W-M Chan; M Ohji; T Y Y Lai; D T L Liu; Y Tano; D S C Lam
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

6.  Choroidal neovascularization in highly myopic eyes after cataract surgery.

Authors:  Kengo Hayashi; Kyoko Ohno-Matsui; Soh Futagami; Seiji Ohno; Takashi Tokoro; Manabu Mochizuki
Journal:  Jpn J Ophthalmol       Date:  2006 Jul-Aug       Impact factor: 2.447

7.  Intravitreal Avastin for choroidal neovascularisation in pathological myopia: the controversy continues.

Authors:  P J Rosenfeld
Journal:  Br J Ophthalmol       Date:  2007-02       Impact factor: 4.638

8.  Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study.

Authors:  Wai-Man Chan; Timothy Y Y Lai; Amy L Wong; David T L Liu; Dennis S C Lam
Journal:  Br J Ophthalmol       Date:  2006-09-20       Impact factor: 4.638

9.  [Unusual myopic fundus alteration].

Authors:  C Münzenberg; F Paulsen; T Kalinski; A Dmitriew; G I W Duncker; S Sel
Journal:  Ophthalmologe       Date:  2009-07       Impact factor: 1.059

10.  Reticular crack lesion in the ocular fundus.

Authors:  Yasushi Isashiki
Journal:  Jpn J Ophthalmol       Date:  2009-01-30       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.